Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Karyopharm Therapeutics Inc

+ Add to Watchlist

KPTI:US

29.9600 USD 0.9400 3.24%

As of 20:10:00 ET on 05/04/2015.

Snapshot for Karyopharm Therapeutics Inc (KPTI)

Open: 28.8900 Day's Range: 28.8900 - 30.5400 Volume: 282,379
Previous Close: 29.0200 52wk Range: 24.0200 - 49.0050 1-Yr Rtn: +2.81%

Stock Chart for KPTI

No chart data available.
  • KPTI:US 29.9600
  • 1D
  • 1M
  • 1Y
29.0200
Interactive KPTI Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for KPTI

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -2.4100
Est. EPS (USD) (12/2015) -3.2660
Est. PEG Ratio -
Market Cap (M USD) 1,069.06
Shares Outstanding (M) 35.68
30 Day Average Volume 298,541
Price/Book (mrq) 4.7374
Price/Sale (ttm) 3,932.5245
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/07/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for KPTI

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for KPTI

Karyopharm Therapeutics, Inc. provides biopharmaceutical products and services. The Company develops and discovers drugs for the treatment of cancer, inflammation, and diseases related to cell proliferation through activity modulation of critical pathways. Karyopham Therapeutics serves the healthcare industry throughout the United States.

Michael G KauffmanCEO/Co-FounderSharon ShachamPresident/Chief Scientific Ofcr
Justin A RenzExec VP/CFO/TreasurerRan FrenkelExec VP:Worldwide Development Ops
More Company Profile & Key Executives for KPTI

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil